Table 9. c.(350TC>CT) and clinical features in 45 patients with missense mutations.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Clinical features | N | c.(350TC>CT) | X2 | P  |
| With Without |
| Age |  |  |  |  |  |
| ≤45>45 | 1629 | 9(56.25%)4(13.79%) | 7(43.75%)25(86.21%) |  | 0.005 |
|  |  |  |  |  |  |
| Tumor size |  |  |  |  |  |
| ≤ 2cm | 23 | 7(30.43%) | 16(69.57%) |  |  |
| >2cm, ≤ 5cm>5cm | 184 | 4(22.22%)2(50.00%) | 14(77.78%)2(50.00%) | 1.456 | 0.567 |
|  |  |  |  |  |  |
| Clinical stage |  |  |  |  |  |
|  I, II | 9 | 0(0.00%) | 9(100.00%) |  |  |
| III，IV | 36 | 13(36.11%) | 23(63.89%) | 4.465 | 0.035 |
| Molecular subtype |  |  |  |  |  |
|   Luminal A | 15 | 2(13.33%) | 13(86.67%) |  |  |
| Luminal B | 12 | 3(25.00%) | 9(75.00%) |  |  |
| HER-2+ | 5 | 2(40.00%) | 3(60.00%) |  |  |
| TNBC | 13 | 6(46.15%) | 7(53.85%) | 4.105 | 0.248 |
| Lymph-node metastasis |  |  |  |  |  |
|  Yes | 27 | 11(40.74%) | 16(59.26%) |  |  |
| No | 18 | 2(11.11%) | 16(88.89%) |  | 0.045 |
|  |  |  |  |  |  |
| ER |  |  |  |  |  |
| +- | 2718 | 5(18.52%)8(44.44%) | 22(81.48%)10(55.56%) | 3.534 | 0.940 |
|  |  |  |  |  |  |
| PR+- | 1530 | 2(13.33%)11(36.67%) | 13(86.67%)19(63.33%) |  | 0.165 |
| HER2+ | 12 | 4(33.33%) | 8(66.67%) |  |  |
| - | 33 | 9(27.27%) | 24(72.73%) |  | 0.721 |
|  |  |  |  |  |  |
| Ki-67 |  |  |  |  |  |
| ≤30% | 23 | 6(26.09%) | 17(73.91%) |  |  |
| >30% | 22 | 7(31.82%) | 15(68.18%) | 0.180 | 0.749 |

Only the first four types are shown. P-value <0.05, statistically significant.